Shares of Hemostemix Inc. (CVE:HEM – Get Free Report) shot up 38.1% on Wednesday . The company traded as high as C$0.15 and last traded at C$0.15. 605,625 shares traded hands during trading, an increase of 51% from the average session volume of 401,760 shares. The stock had previously closed at C$0.11.
Hemostemix Stock Performance
The stock has a market capitalization of C$20.91 million, a PE ratio of -12.00 and a beta of 0.20. The stock has a 50-day moving average price of C$0.09 and a two-hundred day moving average price of C$0.07.
Hemostemix Company Profile
Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia.
Further Reading
- Five stocks we like better than Hemostemix
- How Investors Can Identify and Successfully Trade Gap-Down Stocks
- Driving Forward: Lucid’s Growing Sales and Gravity SUV’s Impact
- The Significance of a Trillion-Dollar Market Cap Goes Beyond a Number
- Why Amazon’s Next Earnings Could Trigger a Stock Breakout
- Stock Ratings and Recommendations: Understanding Analyst Ratings
- With This Kind of Data, The Fed Isn’t Cutting Rates This Year
Receive News & Ratings for Hemostemix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemostemix and related companies with MarketBeat.com's FREE daily email newsletter.
